# Sacituzumab Govitecan With or Without Atezolizumab Immunotherapy in Rare Genitourinary Tumors (SMART) Such as High Grade Neuroendocrine Carcinomas, Adenocarcinoma, and Squamous Cell Bladder/Urinary Tract Cancer, Renal Medullary Carcinoma and Penile C...

> **NCT06161532** · PHASE2 · RECRUITING · sponsor: **National Cancer Institute (NCI)** · enrollment: 60 (estimated)

## Conditions studied

- Small Cell Carcinoma of the Bladder
- Small Cell Carcinoma of the Urinary Tract
- Squamous Cell Carcinoma of the Bladder
- Squamous Cell Carcinoma of the Urinary Tract
- Primary Adenocarcinoma of the Bladder
- Primary Adenocarcinoma of the Urinary Tract
- Renal Medullary Carcinoma
- Squamous Cell Carcinoma of the Penis

## Interventions

- **DRUG:** Sacituzumab govitecan
- **DRUG:** Atezolizumab

## Key facts

- **NCT ID:** NCT06161532
- **Lead sponsor:** National Cancer Institute (NCI)
- **Sponsor class:** NIH
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** RECRUITING
- **Start date:** 2024-08-01
- **Primary completion:** 2027-11-01
- **Final completion:** 2028-11-01
- **Target enrollment:** 60 (ESTIMATED)
- **Last updated:** 2026-04-24


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT06161532

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT06161532, "Sacituzumab Govitecan With or Without Atezolizumab Immunotherapy in Rare Genitourinary Tumors (SMART) Such as High Grade Neuroendocrine Carcinomas, Adenocarcinoma, and Squamous Cell Bladder/Urinary Tract Cancer, Renal Medullary Carcinoma and Penile C...". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT06161532. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*